Lambertus Stanley, Bax Nathalie M, Groenewoud Joannes M M, Cremers Frans P M, van der Wilt Gert Jan, Klevering B Jeroen, Theelen Thomas, Hoyng Carel B
Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
Department for Health Evidence, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6824-6830. doi: 10.1167/iovs.16-20963.
Asymmetry in disease progression between left and right eyes can occur in Stargardt disease (STGD1), and this needs to be considered in novel therapeutic trials with a fellow-eye paired controlled design. This study investigated the inter-eye discordance of best-corrected visual acuity (BCVA) and progression of RPE atrophy in STGD1.
We performed a retrospective cohort study collecting 68 STGD1 patients (136 eyes) with ≥1 ABCA4 variants and ≥0.5-year follow-up on BCVA and fundus autofluorescence. We compared inter-eye correlations of RPE atrophy progression between early-onset (≤10 years), intermediate-onset (11-44), and late-onset (≥45) STGD1 and ABCA4 variant combinations by χ2 tests. We identified associations of discordant baseline BCVA and RPE atrophy with discordant RPE atrophy progression by odds ratios (OR). We defined discordance by differences >1.5 interquartile ranges ± first/third interquartiles.
Progression of RPE atrophy correlated moderately between eyes (ρ = 0.766), which decreased with later onset (P = 9.8 × 10-7) and lower pathogenicity of ABCA4 combinations (P = 0.007). Twelve patients (17.6%) had discordant inter-eye RPE atrophy progression, associated with baseline discordance of RPE atrophy (OR, 6.50 [1.35-31.34]), but not BCVA (OR, 0.33 [0.04-2.85]).
Lower inter-eye correlations are more likely found in late-onset STGD1 and patients carrying low pathogenic ABCA4 combinations. To achieve the highest power in a therapeutic trial, early-phase studies should minimize inter-eye discordance by selecting early-onset STGD1 patients carrying severe ABCA4 variants without evidence of asymmetry at baseline.
在Stargardt病(STGD1)中,左右眼疾病进展可能存在不对称性,在采用对侧眼配对对照设计的新型治疗试验中需要考虑这一点。本研究调查了STGD1患者最佳矫正视力(BCVA)的眼间不一致性以及视网膜色素上皮(RPE)萎缩的进展情况。
我们进行了一项回顾性队列研究,收集了68例STGD1患者(136只眼),这些患者具有≥1个ABCA4变异且对BCVA和眼底自发荧光进行了≥0.5年的随访。我们通过χ2检验比较了早发型(≤10岁)、中间型(11 - 44岁)和晚发型(≥45岁)STGD1以及ABCA4变异组合之间RPE萎缩进展的眼间相关性。我们通过比值比(OR)确定基线BCVA和RPE萎缩不一致与RPE萎缩进展不一致之间的关联。我们通过差异>1.5个四分位数间距±第一/第三四分位数来定义不一致性。
RPE萎缩的进展在两眼之间呈中度相关(ρ = 0.766),随着发病年龄增加相关性降低(P = 9.8×10 - 7),且随着ABCA4组合致病性降低相关性也降低(P = 0.007)。12例患者(17.6%)存在眼间RPE萎缩进展不一致,这与RPE萎缩的基线不一致相关(OR,6.50 [1.35 - 31.34]),但与BCVA无关(OR,0.33 [0.04 - 2.85])。
在晚发型STGD1患者和携带低致病性ABCA4组合的患者中,两眼之间的相关性更可能较低。为了在治疗试验中获得最高效能,早期研究应通过选择早发型、携带严重ABCA4变异且基线无不对称证据的STGD1患者来尽量减少眼间不一致性。